SG11201605316VA - Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases - Google Patents

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Info

Publication number
SG11201605316VA
SG11201605316VA SG11201605316VA SG11201605316VA SG11201605316VA SG 11201605316V A SG11201605316V A SG 11201605316VA SG 11201605316V A SG11201605316V A SG 11201605316VA SG 11201605316V A SG11201605316V A SG 11201605316VA SG 11201605316V A SG11201605316V A SG 11201605316VA
Authority
SG
Singapore
Prior art keywords
sqstm1
inflammation
prevention
treatment
methods
Prior art date
Application number
SG11201605316VA
Inventor
Franco Venanzi
Antonio Concetti
Maria Giovanna Sabbieti
Dimitrios Agas
Vladimir Gabai
Victor Shifrin
Michael Sherman
Alexander Shneider
Original Assignee
Curelab Oncology Inc
Franco Venanzi
Antonio Concetti
Maria Giovanna Sabbieti
Dimitrios Agas
Vladimir Gabai
Victor Shifrin
Michael Sherman
Alexander Shneider
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curelab Oncology Inc, Franco Venanzi, Antonio Concetti, Maria Giovanna Sabbieti, Dimitrios Agas, Vladimir Gabai, Victor Shifrin, Michael Sherman, Alexander Shneider filed Critical Curelab Oncology Inc
Publication of SG11201605316VA publication Critical patent/SG11201605316VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
SG11201605316VA 2013-12-29 2014-12-29 Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases SG11201605316VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361921504P 2013-12-29 2013-12-29
US201461949597P 2014-03-07 2014-03-07
PCT/US2014/072484 WO2015100446A1 (en) 2013-12-29 2014-12-29 Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Publications (1)

Publication Number Publication Date
SG11201605316VA true SG11201605316VA (en) 2016-07-28

Family

ID=53479722

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605316VA SG11201605316VA (en) 2013-12-29 2014-12-29 Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Country Status (10)

Country Link
US (3) US20160324944A1 (en)
EP (1) EP3089753B8 (en)
JP (1) JP6498210B2 (en)
KR (1) KR102422580B1 (en)
CN (1) CN106061501A (en)
AU (1) AU2014369861B2 (en)
CA (1) CA2935232A1 (en)
RU (1) RU2016128557A (en)
SG (1) SG11201605316VA (en)
WO (1) WO2015100446A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605316VA (en) 2013-12-29 2016-07-28 Curelab Oncology Inc Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
WO2020028923A2 (en) * 2018-08-02 2020-02-06 Curelab Oncology, Inc. Compositions and methods relating to p62 for the treatment and prophylaxis of age-related macular degeneration
US20220065875A1 (en) * 2019-02-08 2022-03-03 Ajou University Industry-Academic Cooperation Foundation Biomarker composition for diagnosis of degenerative brain disease
WO2021231652A1 (en) * 2020-05-14 2021-11-18 Curelab Oncology, Inc. Using the p62 plasmid to treat or reduce the severity of coronavirus infections
WO2022129180A1 (en) * 2020-12-15 2022-06-23 Centre National De La Recherche Scientifique Sqstm1 and its use in cancer therapy
WO2023156807A2 (en) * 2021-09-27 2023-08-24 Curelab Oncology, Inc. Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins
CN117603982B (en) * 2024-01-22 2024-04-19 中国医学科学院北京协和医院 P.P374TfsTer18 mutant pathogenic gene of SQSTM1 for amyotrophic lateral sclerosis and application thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
EP0681026A1 (en) 1987-03-02 1995-11-08 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
EP0517751A4 (en) 1990-02-26 1993-03-31 Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
AU2185592A (en) 1991-06-06 1993-01-08 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
US5962224A (en) * 1995-12-19 1999-10-05 Dana-Farber Cancer Institute Isolated DNA encoding p62 polypeptides and uses therefor
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
NZ509966A (en) 1998-08-18 2003-07-25 Res Dev Foundation Recombinant vector comprising a cassette with TET-ON under the control of a heat shock promoter, a cassette with a cloning site for a therapeutic gene, a cassette comprising antisense TET-ON and cassette with a dominative negative TET-ON and its use for metastatic prostate, breast and ovarian cancer
CN1322730A (en) * 2000-05-09 2001-11-21 上海博德基因开发有限公司 New polypeptide-p62cdc6 protein 24 and encoding polynucleotides of the same polypeptide
AU2001280767A1 (en) 2000-07-31 2002-02-13 Active Motif Peptide-mediated delivery of molecules into cells
US20060035823A1 (en) * 2000-08-17 2006-02-16 Seth Lederman Isolated fragments of p62 nucleoporin and uses thereof
EP1372720A4 (en) * 2001-03-02 2006-07-26 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
ATE389015T1 (en) 2001-07-30 2008-03-15 G R M O Groupe De Rech En Mala PAGET BONE DISEASE
ATE421532T1 (en) 2002-05-14 2009-02-15 Jaekyoon Shin THE ROLE OF P62 IN AGE-RELATED DISEASES
EP1578367A4 (en) * 2002-11-01 2012-05-02 Genentech Inc Compositions and methods for the treatment of immune related diseases
GB2443819B (en) 2003-11-17 2009-09-02 Univ Auburn Methods and compositions for inhibiting intracellular aggregate formation
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
GB0412301D0 (en) * 2004-06-02 2004-07-07 Diagenic As Product and method
WO2007044522A1 (en) * 2005-10-05 2007-04-19 Auburn University P62 as a risk determinant for metabolic syndrome
WO2011039734A2 (en) * 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
JP6193231B2 (en) * 2011-08-08 2017-09-06 チュアラボ オンコロジー, インコーポレーテッドCurelab Oncology, Inc. Methods and compositions relating to P62 for the treatment and prevention of cancer
KR20150038915A (en) 2013-10-01 2015-04-09 코닝정밀소재 주식회사 Method of fabricating graphene flake for electrode material of electric double layer capacitor, graphene flake fabricated by the same and electric double layer capacitor including the same by electrode material
KR101594168B1 (en) 2013-10-02 2016-02-15 서울대학교산학협력단 Method for modulating autophagy mediated by p62 through ZZ domain and its use
SG11201605316VA (en) 2013-12-29 2016-07-28 Curelab Oncology Inc Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
WO2020028923A2 (en) * 2018-08-02 2020-02-06 Curelab Oncology, Inc. Compositions and methods relating to p62 for the treatment and prophylaxis of age-related macular degeneration

Also Published As

Publication number Publication date
US20220009985A1 (en) 2022-01-13
JP6498210B2 (en) 2019-04-10
US20190153056A1 (en) 2019-05-23
EP3089753B8 (en) 2020-10-28
CA2935232A1 (en) 2015-07-02
EP3089753A4 (en) 2017-08-09
KR20170016314A (en) 2017-02-13
JP2017502974A (en) 2017-01-26
WO2015100446A1 (en) 2015-07-02
AU2014369861A1 (en) 2016-06-23
KR102422580B1 (en) 2022-07-20
AU2014369861B2 (en) 2018-09-13
US20160324944A1 (en) 2016-11-10
EP3089753A1 (en) 2016-11-09
CN106061501A (en) 2016-10-26
US11098098B2 (en) 2021-08-24
RU2016128557A (en) 2018-02-01
EP3089753B1 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
PL3349783T3 (en) Compositions and methods relating to the treatment of diseases
HK1220980A1 (en) Methods and compositions for treatment of pompe disease
EP3049070A4 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
EP2958936A4 (en) Methods and compositions for treatment of forbes-cori disease
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
IL239851B (en) Methods and compositions for treatment of demyelinating diseases
EP2983791A4 (en) Methods and compositions of treating autoimmune diseases
SG11201605316VA (en) Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EP2986113A4 (en) Compositions and methods for the treatment of brain injury
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP3086809A4 (en) Compositions and methods of treating ocular diseases
PL2892556T3 (en) Compositions and methods relating to the treatment of diseases
EP2945953A4 (en) Thiophene-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
PL3082845T3 (en) Methods and compositions for treatment of peripheral neuropathies
EP3043817A4 (en) Methods and compositions for treatment of chlamydial infection and related diseases and disorders
EP2958591A4 (en) Methods and compositions relating to the treatment of cancer
ZA201508452B (en) Oral formulation for the treatment of cardiovascular diseases
EP2964227A4 (en) Treatment and prophylaxis of kidney diseases
PL3079684T3 (en) Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
EP3089984A4 (en) Novel compounds for the treatment of cancer and inflammatory diseases
GB201516303D0 (en) Compositions and methods relating to the treatment of diseases